NO904367L - CROSS-BONDED ANTIBODIES AND PROCEDURES FOR THEIR PREPARATION. - Google Patents
CROSS-BONDED ANTIBODIES AND PROCEDURES FOR THEIR PREPARATION.Info
- Publication number
- NO904367L NO904367L NO90904367A NO904367A NO904367L NO 904367 L NO904367 L NO 904367L NO 90904367 A NO90904367 A NO 90904367A NO 904367 A NO904367 A NO 904367A NO 904367 L NO904367 L NO 904367L
- Authority
- NO
- Norway
- Prior art keywords
- cross
- antibody
- tumour
- conjugates
- procedures
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Cross-linked antibody conjugates are described which have at least one interchain bridge containing a reporter or effector molecule. The bridge may be the residue of a homo- or hereofunctional cross-linking reagent, and is located away from the antigen binding domains of the antibody. The antibody conjugates have an enhanced binding capacity and in vivo have good blood clearance and, in the presence of a tumour high tumour: blood and tumour: bone ratios. The conjugates are of use in the diagnosis and therapy of e.g. tumours and may be prepared by reaction of a cross-linking reagent with an antibody.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898903022A GB8903022D0 (en) | 1989-02-10 | 1989-02-10 | Chemical compounds |
PCT/GB1990/000213 WO1990009195A1 (en) | 1989-02-10 | 1990-02-12 | Cross-linked antibodies and processes for their preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
NO904367D0 NO904367D0 (en) | 1990-10-09 |
NO904367L true NO904367L (en) | 1990-12-06 |
Family
ID=10651472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO90904367A NO904367L (en) | 1989-02-10 | 1990-10-09 | CROSS-BONDED ANTIBODIES AND PROCEDURES FOR THEIR PREPARATION. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0384624B1 (en) |
JP (1) | JP2975676B2 (en) |
KR (1) | KR910700075A (en) |
AT (1) | ATE123952T1 (en) |
AU (1) | AU632536B2 (en) |
CA (1) | CA2026312A1 (en) |
DE (1) | DE69020182T2 (en) |
FI (2) | FI904975A0 (en) |
GB (2) | GB8903022D0 (en) |
HU (1) | HUT56288A (en) |
IE (1) | IE67320B1 (en) |
IL (1) | IL93361A0 (en) |
NO (1) | NO904367L (en) |
NZ (1) | NZ232490A (en) |
WO (1) | WO1990009195A1 (en) |
ZA (1) | ZA90983B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194594A (en) * | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
GB9112536D0 (en) * | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
DE19911329A1 (en) * | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Radioimmunoconjugate which can be used in human therapy and process for its preparation |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
CA2352532C (en) | 1998-11-27 | 2014-10-14 | Darwin Discovery Ltd. | Compositions and methods for increasing bone mineralization |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
CA2454618C (en) | 2001-07-24 | 2012-04-03 | Biogen Idec Ma, Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
JP2005181192A (en) * | 2003-12-22 | 2005-07-07 | Tacmina Corp | Method of measuring residual chlorine concentration |
US7662921B2 (en) | 2004-05-07 | 2010-02-16 | Astellas Us Llc | Methods of treating viral disorders |
US8182790B2 (en) | 2004-11-22 | 2012-05-22 | Ge Healthcare As | Contrast agents |
DE102005034950A1 (en) | 2005-07-22 | 2007-02-01 | Tesa Ag | Dispenser for the production of an adhesive tape tube |
JP2009529917A (en) | 2006-03-22 | 2009-08-27 | ヴァイラル ロジック システムズ テクノロジー コーポレーション | Methods for identifying target polypeptides and their use for the treatment of immunological disorders |
US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4751286A (en) * | 1985-11-19 | 1988-06-14 | The Johns Hopkins University | Protein label and drug delivery system |
GB8603537D0 (en) * | 1986-02-13 | 1986-03-19 | Parker D | Conjugate compound |
GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
-
1989
- 1989-02-10 GB GB898903022A patent/GB8903022D0/en active Pending
-
1990
- 1990-02-09 ZA ZA90983A patent/ZA90983B/en unknown
- 1990-02-12 AT AT90301441T patent/ATE123952T1/en not_active IP Right Cessation
- 1990-02-12 DE DE69020182T patent/DE69020182T2/en not_active Expired - Lifetime
- 1990-02-12 EP EP90301441A patent/EP0384624B1/en not_active Expired - Lifetime
- 1990-02-12 NZ NZ232490A patent/NZ232490A/en unknown
- 1990-02-12 HU HU901641A patent/HUT56288A/en unknown
- 1990-02-12 IL IL93361A patent/IL93361A0/en unknown
- 1990-02-12 JP JP2503004A patent/JP2975676B2/en not_active Expired - Lifetime
- 1990-02-12 IE IE49490A patent/IE67320B1/en not_active IP Right Cessation
- 1990-02-12 KR KR1019900702231A patent/KR910700075A/en not_active Application Discontinuation
- 1990-02-12 CA CA002026312A patent/CA2026312A1/en not_active Abandoned
- 1990-02-12 AU AU50475/90A patent/AU632536B2/en not_active Ceased
- 1990-02-12 WO PCT/GB1990/000213 patent/WO1990009195A1/en active Application Filing
- 1990-10-09 FI FI904975A patent/FI904975A0/en not_active Application Discontinuation
- 1990-10-09 GB GB9021894A patent/GB2237020B/en not_active Revoked
- 1990-10-09 NO NO90904367A patent/NO904367L/en unknown
- 1990-10-09 FI FI904974A patent/FI904974A0/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
FI904975A0 (en) | 1990-10-09 |
GB2237020B (en) | 1993-04-14 |
IE900494L (en) | 1990-08-10 |
ATE123952T1 (en) | 1995-07-15 |
DE69020182D1 (en) | 1995-07-27 |
JPH03504644A (en) | 1991-10-09 |
ZA90983B (en) | 1991-10-30 |
EP0384624A2 (en) | 1990-08-29 |
CA2026312A1 (en) | 1990-08-11 |
GB8903022D0 (en) | 1989-03-30 |
DE69020182T2 (en) | 1995-11-30 |
HUT56288A (en) | 1991-08-28 |
IE67320B1 (en) | 1996-03-20 |
EP0384624B1 (en) | 1995-06-21 |
JP2975676B2 (en) | 1999-11-10 |
FI904974A0 (en) | 1990-10-09 |
IL93361A0 (en) | 1990-11-29 |
WO1990009195A1 (en) | 1990-08-23 |
EP0384624A3 (en) | 1990-11-14 |
NO904367D0 (en) | 1990-10-09 |
AU5047590A (en) | 1990-09-05 |
KR910700075A (en) | 1991-03-13 |
HU901641D0 (en) | 1991-03-28 |
NZ232490A (en) | 1992-09-25 |
GB9021894D0 (en) | 1990-11-28 |
GB2237020A (en) | 1991-04-24 |
AU632536B2 (en) | 1993-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO904368L (en) | CROSS-BONDED ANTIBODIES AND PROCEDURES FOR THEIR PREPARATION. | |
NO904367D0 (en) | CROSS-BONDED ANTIBODIES AND PROCEDURES FOR THEIR PREPARATION. | |
DK2289A (en) | MONOCLONAL ANTIBODIES AND THEIR PREPARATION AND USE | |
ATE382370T1 (en) | ANTIBODIES-SERUM PROTEIN HYBRID | |
BR0112542A (en) | Compositions and methods for ovarian cancer therapy and diagnosis | |
DE69128791D1 (en) | MODIFIED ANTIBODIES WITH CONTROLLED CLEARANCE TIME | |
ATE255633T1 (en) | HUMAN B-LYMPHOBLASTOID CELL LINE WHICH SECRETS ANTIGANGLIOSIDE ANTIBODIES | |
GB2278357B (en) | Humanised antibodies directed against A33 antigen | |
PT81093B (en) | METHOD FOR PREPARING A THERAPEUTIC COMPOSITION FOR TREATMENT OF A TUMOR | |
Rhind | Crosslinked antibodies and processes for their preparation | |
ATE95426T1 (en) | HUMAN CARCINOMA-ASSOCIATED ANTIGEN AND ANTIBODIES BINDING TO THIS ANTIGEN. | |
JPH02170052A (en) | Immune globulin m antibody fragment combined with reagent | |
BR9815775A (en) | High affinity humanized carcinoembryonic (CEA) monoclonal antibodies |